Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN), has highlighted the advocacy efforts the organization was involved in from the local level to the federal level.
Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN), has highlighted the advocacy efforts the organization was involved in from the local level to the federal level.
Transcript
What are some of the major advocacy efforts that ACS CAN has been involved in over the past year?
ACS CAN is a national organization and we work on the local level—sometimes as local as cities—the state level, and at the federal level. We have a presence in all 50 states and will advocate on things as small as smoke-free ordinances in a given city to things as large as healthcare reform, 21st Century Cures, things like that. We were very active in 21st Century Cures. That was a very bipartisan, open process, where the input of patient groups and all stakeholders was invited. And we provided testimony, lots of commentary on that. And we felt like we had a great opportunity to help shape and influence the legislation.
The other major issue that we really spent a lot of time on over the last 6 months is healthcare reform. The Affordable Care Act instituted a number of protections for cancer patients—things like abolishing lifetime caps, getting rid of preexisting condition exclusions, and community rating. So, as Congress decided to revisit a lot of the Affordable Care Act, and the way insurance is regulated and financed, we’ve stepped in and made sure that the provisions that are important to cancer patients, again things like lifetime caps and guaranteed issue, have maintained in any proposals going forward.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More